Movement Alert｜Alnylam Pharmaceuticals Rises 5.47% in Regular Trading, Multiple Institutions Call Prior 28% Selloff Overdone

Market Focus08-03

On August 3, Alnylam Pharmaceuticals rose 5.47% in regular trading, trading at approximately $218.82/share, with turnover of $174 million. The rebound follows a 28%-plus single-day plunge on July 30 triggered by Q2 revenue missing expectations and a full-year guidance cut.

Multiple institutions maintained positive ratings after the selloff, calling the decline overdone. RBC Capital Markets kept its Outperform rating while lowering its price target to $350 from $445, noting Amvuttra growth and pipeline progress still support upside. Stifel maintained a Buy rating with a $318 target. The company's Q2 adjusted EPS of $1.84 beat consensus of $1.55 by 18.71%, representing a 475% year-over-year increase. Management reaffirmed its target of delivering over 25% total revenue CAGR through 2030, though RBC noted the language appeared more measured. The full-year net product revenue guidance was lowered to $4.70-$5.10 billion from $4.90-$5.30 billion as second-line Amvuttra demand normalized. The collective institutional support eased market panic and drove a technical rebound.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1100614524?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-03 22:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100614524","market":"us","top_or_hot":-1,"title":"Movement Alert｜Alnylam Pharmaceuticals Rises 5.47% in Regular Trading, Multiple Institutions Call Prior 28% Selloff Overdone","media":"Market Focus","content":"<p><p>On August 3, Alnylam Pharmaceuticals rose 5.47% in regular trading, trading at approximately $218.82/share, with turnover of $174 million. The rebound follows a 28%-plus single-day plunge on July 30 triggered by Q2 revenue missing expectations and a full-year guidance cut.</p><p>Multiple institutions maintained positive ratings after the selloff, calling the decline overdone. RBC Capital Markets kept its Outperform rating while lowering its price target to $350 from $445, noting Amvuttra growth and pipeline progress still support upside. Stifel maintained a Buy rating with a $318 target. The company's Q2 adjusted EPS of $1.84 beat consensus of $1.55 by 18.71%, representing a 475% year-over-year increase. Management reaffirmed its target of delivering over 25% total revenue CAGR through 2030, though RBC noted the language appeared more measured. The full-year net product revenue guidance was lowered to $4.70-$5.10 billion from $4.90-$5.30 billion as second-line Amvuttra demand normalized. The collective institutional support eased market panic and drove a technical rebound.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Alnylam Pharmaceuticals Rises 5.47% in Regular Trading, Multiple Institutions Call Prior 28% Selloff Overdone</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Alnylam Pharmaceuticals Rises 5.47% in Regular Trading, Multiple Institutions Call Prior 28% Selloff Overdone\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-03 22:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 3, Alnylam Pharmaceuticals rose 5.47% in regular trading, trading at approximately $218.82/share, with turnover of $174 million. The rebound follows a 28%-plus single-day plunge on July 30 triggered by Q2 revenue missing expectations and a full-year guidance cut.</p><p>Multiple institutions maintained positive ratings after the selloff, calling the decline overdone. RBC Capital Markets kept its Outperform rating while lowering its price target to $350 from $445, noting Amvuttra growth and pipeline progress still support upside. Stifel maintained a Buy rating with a $318 target. The company's Q2 adjusted EPS of $1.84 beat consensus of $1.55 by 18.71%, representing a 475% year-over-year increase. Management reaffirmed its target of delivering over 25% total revenue CAGR through 2030, though RBC noted the language appeared more measured. The full-year net product revenue guidance was lowered to $4.70-$5.10 billion from $4.90-$5.30 billion as second-line Amvuttra demand normalized. The collective institutional support eased market panic and drove a technical rebound.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALNY","symbol_name":"阿尔尼拉姆制药公司","start_time":0,"source_url":"","article_id":"1100614524","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100614524","pubTimestamp":1785766072,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 3, Alnylam Pharmaceuticals rose 5.47% in regular trading, trading at approximately $218.82/share, with turnover of $174 million. The rebound follows a 28%-plus single-day plunge on July 30...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALNY":"阿尔尼拉姆制药公司"},"translate_title":"走势警报|Alnylam Pharmaceuticals 常规交易中上涨 5.47%，多家机构看涨期权此前抛售 28% 过度","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALNY":1},"content_text":"On August 3, Alnylam Pharmaceuticals rose 5.47% in regular trading, trading at approximately $218.82/share, with turnover of $174 million. The rebound follows a 28%-plus single-day plunge on July 30 triggered by Q2 revenue missing expectations and a full-year guidance cut.Multiple institutions maintained positive ratings after the selloff, calling the decline overdone. RBC Capital Markets kept its Outperform rating while lowering its price target to $350 from $445, noting Amvuttra growth and pipeline progress still support upside. Stifel maintained a Buy rating with a $318 target. The company's Q2 adjusted EPS of $1.84 beat consensus of $1.55 by 18.71%, representing a 475% year-over-year increase. Management reaffirmed its target of delivering over 25% total revenue CAGR through 2030, though RBC noted the language appeared more measured. The full-year net product revenue guidance was lowered to $4.70-$5.10 billion from $4.90-$5.30 billion as second-line Amvuttra demand normalized. The collective institutional support eased market panic and drove a technical rebound.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1100614524","isCrawlerRequest":true}